Vertex Pharmaceuticals Inc / Ma
—- Market cap
- —
- Debt
- —
- Cash
- −$5.08B
Complete market value, debt and cash evidence is required for enterprise value.
Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
FY 2026 · Mkt capMarket cap $195.44B · View financials
Decision snapshot: VRTX stock price vs STX: inconclusive — current versus $950.42 implied using P/E multiple.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at STX's multiple
Implied fair value · at VRTX's multiple
Needs VRTX P/E.
Snapshot Sep 10, 2026, 4:00 PM ET
Metric by metric
Where each company leads, and how wide the gap is.
Growth lag
Reported gross margin
Operating income + D&A
Lower is better
Not comparable
Lower leverage
Statements
Annual statements in reported currencies, with calculations and source evidence.
Values retain reported currencies and share bases. Select a figure to inspect its period, calculation and filing inputs. Differences require compatible units and periods.
Explore enterprise value and market valuation multiples in the valuation sections.
Trendline
Nine period-end years of reported revenue, earnings, and margins. Periods and currencies are shown with the data.
Price framework
USD market cap plus reported borrowing debt, less cash and equivalents. This EV proxy excludes investments, preferred stock and noncontrolling-interest adjustments.
Complete market value, debt and cash evidence is required for enterprise value.
Complete market value, debt and cash evidence is required for enterprise value.
Price framework
The same filing-backed model used on each company's valuation page, with company-specific inputs and calculated scenarios.
VERTEX PHARMACEUTICALS INC / MA · implied price per share
Debt and bridge-cash inputs are required to translate enterprise value into equity value.
Seagate Technology Holdings plc · implied price per share
Debt and bridge-cash inputs are required to translate enterprise value into equity value.
Balance sheet health
Inspect reported liquidity and leverage alongside historical financial-health checks.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
AMGEN INC
VRTX vs AMGN
Gilead Sciences, Inc.
VRTX vs GILD
BIOGEN INC.
VRTX vs BIIB
Moderna, Inc.
VRTX vs MRNA
Illumina, Inc.
VRTX vs ILMN
WESTERN DIGITAL CORP
VRTX vs WDC
NetApp, Inc.
VRTX vs NTAP
Dell Technologies Inc.
VRTX vs DELL
Hewlett Packard Enterprise Co
VRTX vs HPE
QUANTUM CORP /DE/
VRTX vs QMCO
Cash excludes investments. EBITDA is an operating-income-plus-D&A proxy. Missing borrowing categories remain unavailable; select a value to inspect its inputs.
LLM-powered synthesis
An explanation of the financial evidence. Check its snapshot date against the figures above.
This explanation uses an earlier data snapshot or evidence version. Review its generation date and the current figures, or refresh after signing in.
If you believe VRTX’s higher-margin business model and stronger balance sheet deserve a valuation premium over STX, then favor VRTX because its P/E, EV/EBITDA, and leverage are all more attractive than STX’s despite slower growth.
VRTX appears cheaper than STX on earnings and enterprise-value multiples, with a 32.4x P/E versus 58.5x for STX and 25.0x EV/EBITDA versus 40.4x. The current price of $496.07 implies material upside to the model price of $895.79, although STX-implied range is wide and the DCF range is far below the market price.
Supporting Metrics